<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562079</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2011/37</org_study_id>
    <nct_id>NCT02562079</nct_id>
  </id_info>
  <brief_title>Vasculopathy, Inflammation and Systemic Sclerosis</brief_title>
  <acronym>VISS</acronym>
  <official_title>Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Française de Rhumatologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a study of basic research with mechanistically objectives and including clinical
      biological samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic sclerosis (SSc) is a rare and severe disease characterised by a fibrotic process and
      an incompletely elucidate physiopathology. Several shared featured have been identified
      between SSc and another autoimmune disease, the systemic lupus erythematous (SLE) as an
      interferon-alpha signature, the role of platelets and the polymorphism of OX40 ligand
      (OX40L). In SLE, OX40L has been shown highly linked to the active form of the disease, was
      increased by the CD40L of platelets and induced the CD8 cytotoxicity while inhibiting the
      suppressive functions of regulator T lymphocytes. The third main factor of the SSc
      physiopathology apart from autoimmunity and fibrosis is the vasculopathy with an important
      role of endothelial cells (EC). They turned out to be half-professional antigen presenting
      cells and can modulate the adaptive immunity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of OX40L expression in endothelial cells and skin biopsies.</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>subjects Localised sclerosis diagnosed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>subjects Sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>biological features of the standard follow-up
2 more blood tube for the biological collection (serum and PBMC)</description>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
    <arm_group_label>subjects Localised sclerosis diagnosed</arm_group_label>
    <arm_group_label>subjects Sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Skin biopsies</description>
    <arm_group_label>subjects SSc diagnosed</arm_group_label>
    <arm_group_label>subjects Localised sclerosis diagnosed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 75.

          -  SSc diagnosed according to the American College of Rheumatology (ACR) criteria.

          -  With skin manifestations since less than 10 years.

          -  Localised sclerosis (LSc) diagnosed, morphea type.

        Exclusion Criteria:

          -  Age inferior to 18 or upper than 75.

          -  Skin manifestations since more than 10 years.

          -  Haemostasis diseases (independent from treatments).

          -  Stem cell transplant.

          -  Immunosuppressive treatments in the last 6 months.

          -  Associate autoimmune disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elise TRUCHETET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Rhumatologie - Tripode - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T lymphocyte</keyword>
  <keyword>OX40/OX40L</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

